Bristol-Myers Squibb Is Undervalued
August 19, 2019 at 17:36 PM EDT
Bristol-Myers Squibb is under considerable pressure, the stock has declined by more than 25% from its highs of the year due to generalized negativity towards the drug manufacturing sector and the uncertainty produced by the Celgene acquisition.